208. rituximab and Late-Onset Neutropenia: A Retrospective Analysis of Rituximab-Treated Adult Rheumatoid Arthritis Patients in a Teaching Hospital

Pathak, Himanshu; Cefai, Erika; Yates, Max; Marshall, Tarnya

doi:10.1093/rheumatology/kex062.209

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-CD20: There were 24 included studies in which anti-CD20 medications were the exposure of interest, including three placebo-controlled RCTs [ 47 , 86 , 87 ], one pooled safety study of placebo-controlled RCTs [88] , five cohort studies [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , and fifteen case series [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] , [101] , [102] , [103] , [104] , [105] , [106] . Overall, there were limited data for the outcomes of interest in studies that evaluated anti-CD20 therapy.…”

Section: Resultsmentioning

confidence: 99%

Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

Kilian

Chock

Huang

et al. 2020

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Highlights This scoping review provides an up-to-date overview of published evidence regarding the frequency and severity of acute viral respiratory AEs related to antirheumatic disease therapies. Glucocorticoid use was associated with a higher frequency of acute upper and lower respiratory viral events. Mild viral respiratory infections occurred more frequently in several studies in which patients were treated with JAKi, most notably at higher doses. TNFi and IL-17 inhibitors seemed to be associated with higher frequency of mild viral respiratory infections such as URTI and nasopharyngitis. Our review identifies a knowledge gap for most antirheumatic medications and their acute respiratory viral complications; in the context of the COVID-19 pandemic, increased widespread respiratory viral PCR testing offers immediate research opportunities to clarify the safety of antirheumatic therapies in terms of viral respiratory complications.

show abstract